Impact of iGlarLixi on Glycaemic Control Depth and Variability in Asian Pacific People With Type 2 Diabetes: A Post Hoc Analysis of LixiLan-O-AP and LixiLan-L-CN.
Diabetes Obes MetabJul 1, 2026 (epub)
Jiaying Ni, Jingyi Lu, Fei Gao et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of two phase 3 trials evaluated the effects of iGlarLixi on glycaemic control depth, variability, and postprandial glucose in Asian Pacific individuals with type 2 diabetes. Results showed that iGlarLixi significantly improved the derived time in tight range (dTITR) by 15.03% compared to insulin glargine and 29.14% compared to lixisenatide.
Key findings
- iGlarLixi increased dTITR by 15.03% vs iGlar and 29.14% vs Lixi in LixiLan-O-AP.
- At EOT, >50% dTITR was achieved in 67.2% of patients on iGlarLixi.
- iGlarLixi showed greater reductions in glycaemic variability metrics compared to iGlar or Lixi.
- iGlarLixi achieved higher rates of 2-h PPG <10.0 mmol/L at EOT.
Why it matters
Improving glycaemic control depth and reducing variability are crucial for managing type 2 diabetes, as they can lead to better long-term outcomes and reduced risk of complications. This study highlights the potential of iGlarLixi as an effective treatment option.